1. Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea 
Reginald V. Fant, Jack E. Henningfield, Brooks D. Cash, Leonard S. Dove, Paul S. Covington 
Clinical Gastroenterology and Hepatology 
Volume 15, Issue 7, Pages e6 (July 2017)
DOI: /j.cgh
Copyright © 2017 AGA Institute Terms and Conditions

2. Figure 1
SOWS scores 0, 1, 2, 3, and >3 days after treatment discontinuation.
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions